Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
11
2023 to 2026
Breakthrough
5
Accelerated
5
Priority review
8
Orphan
9
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 0 | 0 |
| 2024 | 3 | 4 |
| 2025 | 1 | 0 |
| 2026 | 3 | 0 |
11 approvals
Newest first. Hover a badge for what it means.
- Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
To treat metastatic pancreatic cancer
- Lynavoy (Linerixibat) · InterceptMar 17, 2026
To treat cholestatic pruritus associated with primary biliary cholangitis
- Nereus (Tradipitant) · Vanda Pharms INCDec 30, 2025
To treat vomiting associated with motion
- Bizengri (Zenocutuzumab-Zbco) · Merus N.V.Dec 4, 2024Original approval · BLA 761352NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat non-small cell lung cancer and pancreatic adenocarcinoma
- Ziihera (Zanidatamab-Hrii) · Jazz PharmsNov 20, 2024Original approval · BLA 761416NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer
- Vyloy (Zolbetuximab-Clzb) · AstellasOct 18, 2024
To treat gastric or gastroesophageal junction adenocarcinoma
- Livdelzi (Seladelpar Lysine) · Gilead Sciences INCAug 14, 2024Original approval · NDA 217899NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat primary biliary cholangitis (PBC)
- Iqirvo (Elafibranor) · IpsenJun 10, 2024Original approval · NDA 218860NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat primary biliary cholangitis in combination with ursodeoxycholic acid
- Rezdiffra (Resmetirom) · MadrigalMar 14, 2024Original approval · NDA 217785NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
- Tevimbra (Tislelizumab-Jsgr) · BeigeneMar 13, 2024
To treat unresectable or metastatic esophageal squamous cell carcinoma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.